Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The BINC-B trial is a diagnostic and interventional study in which various function imaging
methods as Magnetic Resonance Imaging (PWI, DWI and DCE-MRI) and will be compared with common
imaging methods (mammography and/or ultrasound) to investigate if an early response to a
combined neoadjuvant chemotherapy in operable or potentially operable breast cancer. For
breast cancer patients with positive HER-2, additional Herceptin could improve the response
further. In this study the efficacy of combined neoadjuvant therapy with or without Herceptin
should be evaluated and the role in predicting the tumor response with different imaging
should be estimated.